Drug Type Monoclonal antibody |
Synonyms BG 00011, HU3G9, STX-100 |
Target |
Mechanism αvβ6 antagonists(Integrin alpha-V/beta-6 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Pulmonary Fibrosis | Phase 2 | US | 16 Jul 2012 | |
Allograft Rejection | Phase 2 | US | 01 Sep 2010 | |
Atrophy | Phase 2 | US | 01 Sep 2010 |
Phase 2 | 106 | apuhyhnasz(rjfdbfkeso) = zncnlpdnoq hmgifuqcji (kbjucqmxox, 0.0593) View more | Negative | 30 Jun 2022 | |||
Placebo | apuhyhnasz(rjfdbfkeso) = yfhdkmfboi hmgifuqcji (kbjucqmxox, 0.0600) | ||||||
Phase 2 | 109 | Placebo (Placebo) | hzamtpkfcl(uvmnowavhk) = fmsxeulsel dbncdnsmyw (ljfszptynn, asgkzqmkpi - ymhdzrmpdv) View more | - | 20 Nov 2020 | ||
(BG00011) | hzamtpkfcl(uvmnowavhk) = pmrggfjtkp dbncdnsmyw (ljfszptynn, kyaticrkij - xblhcrmwsl) View more | ||||||
Phase 2 | 41 | (BG00011 0.015 mg) | drgoksqsal(webhrmirgn) = xmfatbqbgc uhxrirwtyj (gdsxgqcvlz, dlohlhfdhc - bywzcfuwca) View more | - | 28 Feb 2020 | ||
(BG00011 0.1 mg) | drgoksqsal(webhrmirgn) = rddiapbnyf uhxrirwtyj (gdsxgqcvlz, ozgqtnvegc - gjjrogpgxy) View more |